Trials / Completed
CompletedNCT06336018
A Research Study on Etavopivat in Participants With and Without Liver Disease
A Multi-centre, Open-label, Parallel-group Study Investigating the Pharmacokinetics, Safety and Tolerability After a Single Dose of Oral Etavopivat in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Participants With Normal Hepatic Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study investigates an investigational drug called etavopivat in participants with hepatic impairments and participants with normal hepatic function (matched controls). During the study, all participants will be given a single oral dose of etavopivat. All participants will take the etavopivat orally together with water. After dosing, the study will last for 7 to 9 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etavopivat | Participants will receive a single dose of etavopivat orally. |
Timeline
- Start date
- 2024-05-20
- Primary completion
- 2025-08-01
- Completion
- 2025-08-01
- First posted
- 2024-03-28
- Last updated
- 2025-10-14
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06336018. Inclusion in this directory is not an endorsement.